Evidence map›Paper›PMID 31844581›Full record

ArticlePeerJ2019

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension.

Jie Wei, Zhiyang Zhou, Zhijie Xu, Shuangshuang Zeng, Xi Chen, Xiang Wang, Wanli Liu, Min Liu, Zhicheng Gong, Yuanliang Yan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Current Status of Research on Losartan in Tumour Therapy.Journal of cellular and molecular medicine · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Risk of lung cancer and renin-angiotensin blockade: a concise review.Journal of cancer research and clinical oncology · 2021
    Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jie Wei *Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhiyang Zhou *Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhijie XuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shuangshuang ZengDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xi ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiang WangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wanli LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Min LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhicheng GongDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuanliang YanDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRenin-angiotensin system blockers (RASBs), which include angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-2 receptor 1 blockers (ARBs), have been reported to be associated with lung cancer metastasis, radiotherapy and chemotherapy. Until now, very limited clinical data for RASBs' diagnostic and prognostic effects has existed for lung cancer chemotherapy in Chinese patients.

methodsThere were a total of 678 lung cancer patients with hypertension, of which 461 (68%) were in the non-RASBs group and 217 (32%) were in the RASBs group. Patients' gender, age, smoking status, histologic differentiation, tumor size, pathological grade, lymph node metastasis, pathological stage and progression-free survival (PFS) were retrospectively analyzed between these two groups. The clinical effects of ACEIs and ARBs in lung cancer patients were compared via t tests, and

resultsSignificant differences were observed in lymph node metastasis between the RASBs and non-RASBs groups. The RASBs group (62.8% vs 71.7%,

conclusionIn this study, we showed that the use of RASBs is a positive factor for pathological stage and prognosis of lung cancer patients. Therefore, it is necessary to actively evaluate medical history, especially the use of anti-hypertension medication, in patients with lung cancer and reflect medical history in the treatment and management plans of these patients.

Indexed as

Clinical analysisHypertensionLung cancerRenin-angiotensin system blockers

Identifiers

PMID31844581
PMCPMC6910116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.